<DOC>
	<DOCNO>NCT01060514</DOCNO>
	<brief_summary>The purpose study determine high dose Vinorelbine Pazopanib give together without cause severe side effect . Also , study evaluate effect ( good bad ) treatment patient cancer .</brief_summary>
	<brief_title>Pazopanib + Vinorelbine Non Small Cell Lung Cancer ( NSCLC ) Breast Cancer</brief_title>
	<detailed_description>This study involve investigational drug call pazopanib combination chemotherapy drug vinorelbine . An investigational drug drug approve U.S. Food Drug Administration ( FDA ) use United States . Vinorelbine FDA approve treat patient NSCLC breast cancer . Pazopanib vascular endothelial growth factor inhibitor , mean may prevent tumor grow blood vessel thereby interfere growth tumor . Participants study assign one three group group receive high dose vinorelbine pazopanib previous group . Vinorelbine give needle vein day 1 8 21 day study treatment cycle . Pazopanib pill take mouth every day 21 day study treatment cycle .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Age &gt; 18 year Patients must diagnosis breast cancer non small cell lung cancer Patients must evaluable disease Women childbearing potential sexually active male must commit use effective contraception study . Patients must give sign , informed consent prior registration study . Patients must pregnant and/or lactate . Patients must receive investigational agent . No prior exposure vinorelbine VEGF inhibitor treatment metastatic disease Patients must receive prior therapy ( include radiation , surgery , and/or chemotherapy ) within 30 day History allergic reaction attribute compound similar chemical biologic composition pazopanib vinorelbine . Patients receive 2 prior chemotherapy regimen lung cancer 3 prior chemotherapy regimen breast cancer . This criterion discuss study doctor . Must uncontrolled illness include , limited : ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmic , psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>Breast cancer</keyword>
</DOC>